A Research Guide for
IBD

• Blood tests: Complete blood count (anemia, high white count), CRP and/or ESR (inflammation markers), liver enzymes (PSC screen), iron studies, vitamin B12, vitamin D, albumin (nutrition/severity).
• Stool tests: Fecal calprotectin (the most important non-invasive inflammation marker for IBD), stool cultures and C. difficile (to rule out infections that mimic or coexist with IBD).
• Colonoscopy with ileoscopy and biopsies: The cornerstone test. The endoscopist should reach the terminal ileum and take biopsies from multiple sites — including normal-looking areas — to map disease and to look for microscopic inflammation.
• Upper endoscopy (EGD): Recommended in Crohn's disease, especially if there are upper GI symptoms.
• Cross-sectional imaging: MR enterography (preferred for young patients, no radiation) or CT enterography to evaluate the small bowel in Crohn's, look for complications (strictures, fistulas, abscesses), and assess disease extent.
• Intestinal ultrasound (IUS): Increasingly used — non-invasive, no radiation, can be done in clinic, very effective for monitoring once diagnosis is established.
• Pre-biologic workup: TB testing (PPD or IGRA), hepatitis B serologies, varicella status, MMR titers, HIV if appropriate, and TPMT/NUDT15 testing before thiopurines.

For ulcerative colitis, severity is graded using the Mayo score (combines stool frequency, rectal bleeding, endoscopic appearance, and physician global assessment) and disease extent (proctitis < left-sided < extensive/pancolitis). Acute severe UC is defined by Truelove and Witts criteria and is a medical emergency.

For Crohn's disease, the Montreal classification captures age at diagnosis (A1/A2/A3), location (L1 ileal, L2 colonic, L3 ileocolonic, L4 upper GI), and behavior (B1 inflammatory, B2 stricturing, B3 penetrating, with "p" added for perianal disease). The Crohn's Disease Activity Index (CDAI) is used in trials; in clinic, doctors often use simpler measures plus objective markers.

Modern severity assessment also includes prognosis — markers of "high-risk" disease that warrant earlier aggressive therapy (young age at diagnosis, deep ulcers on scope, perianal disease, extensive Crohn's, steroid requirement at presentation, weight loss, very high calprotectin).

Before: A clear liquid diet the day before and a strong laxative prep. Tell your doctor about all medications — some, like blood thinners, may need to be paused. If you have a stricture or are very symptomatic, the prep can be modified.

During: Performed under sedation. The endoscopist looks at the lining, takes pictures, and biopsies multiple sites. You won't remember most of it.

After: You'll be groggy for a few hours. The endoscopist often shares preliminary findings (what they saw) on the day. The biopsy report takes about a week.

For IBD, colonoscopy is not just a diagnostic test — it's a monitoring tool that often guides treatment decisions for years to come. Each colonoscopy is a chance to verify that what you and your doctor are doing is working.

Intestinal ultrasound (IUS) is one of the most important advances in IBD monitoring in recent years. Many patients never encounter it unless they see a specialist who uses it routinely. Here is what you need to know.

What it is: A specialised ultrasound technique in which a handheld probe is placed on your abdomen (similar to a pregnancy ultrasound). Using high-frequency sound waves, the operator can visualise the walls of your bowel in real time — measuring bowel wall thickness, assessing vascularity (blood flow, a marker of inflammation), identifying strictures, and detecting complications like abscesses and fistulas.

What makes it different from other IBD tests:

• No prep required — no bowel cleanse, no fasting.
• No radiation — unlike CT scan, it uses sound waves only.
• Done in clinic — can be performed right in the gastroenterology office, often at the same appointment as your consultation.
• Repeat-friendly — can be done monthly if needed to track response to therapy.
• Transmural visualisation — sees through the full thickness of the bowel wall, detecting changes that colonoscopy (which only sees the inner surface) misses.

What it can and cannot do:

• Excellent for: monitoring known disease in the terminal ileum and colon, detecting response to therapy (bowel wall thinning with treatment is a good sign), identifying complications in Crohn’s, tracking post-operative recurrence.
• Limited by: operator training (technique-dependent), body habitus (harder in some patients), and limited visualisation of the rectum and proximal small bowel.
• Does not replace colonoscopy for: initial diagnosis (biopsies required), dysplasia surveillance, or rectal assessment.

Where is IUS available? Widely used in Europe, Canada, and Australia for a decade. In the United States, it is rapidly expanding at academic IBD centres including the University of Utah Health IBD Center. A 2024 AGA Clinical Practice Update formally endorsed IUS for IBD monitoring at centres with appropriate expertise. Ask your IBD team whether they offer it.

Fecal calprotectin is the most important non-invasive test in IBD monitoring. Yet many patients don’t fully understand what their number means or how it should drive decisions. Here is a plain-language guide.

What it measures: Calprotectin is a protein released by neutrophils (a type of white blood cell) when they migrate into the intestinal wall during inflammation. The more inflamed your gut, the more calprotectin leaks into your stool. The test requires a small stool sample collected at home and mailed or brought to the lab.

Reference ranges (most labs use similar cutoffs):

• < 50 µg/g — Normal. Inflammation is very unlikely. This is the target.
• 50–200 µg/g — Borderline / indeterminate. Can reflect mild inflammation or non-IBD causes (NSAID use, GI infection, IBS overlap). Your team may repeat the test.
• 200–600 µg/g — Elevated. Active inflammation likely. Even if you feel "okay," the disease is active at the tissue level. Treatment adjustment should be considered.
• > 600 µg/g — Significantly elevated. Substantial active inflammation. Therapy review is urgent.
• > 1,000 µg/g — Severely elevated; often correlates with extensive mucosal disease. May require urgent endoscopic reassessment.

How it guides treat-to-target decisions:

• High on a new biologic → the drug may not be working; check drug levels (TDM) and consider dose optimisation or switch.
• Falling over 6 months (e.g., 1,200 → 600 → 200 → < 50) → encouraging early response; continue and recheck.
• Rising from a previous normal → early signal of relapse; address before it becomes a full flare.
• Stays elevated despite adequate drug levels → mechanistic failure; switch drug class.

Caveats: Calprotectin can be falsely low in rectal-only disease (proctitis) and falsely elevated by NSAIDs, infections, or IBS. It is a tool, not a standalone decision-maker. Ask your team: How often should I check calprotectin? What number are we targeting? What number would trigger a same-week callback?

• Have we ruled out infections that can mimic IBD (C. difficile, parasites, TB)?
• What did the biopsies actually show — chronic inflammation, granulomas, dysplasia?
• Do I have any "high-risk" features that would push toward earlier aggressive therapy?
• Is my disease likely to be aggressive or relatively mild based on what we know?
• Should I have an MRI enterography or intestinal ultrasound to assess the small bowel?
• Have we screened me for TB and hepatitis B before starting biologics?
• What vaccinations should I get before starting immunosuppressing therapy?
• Should I see a colorectal surgeon as part of my baseline care?

5-ASA (mesalamine): The mainstay for mild-to-moderate ulcerative colitis, in both oral and rectal (suppository/enema) forms. For left-sided UC and proctitis, rectal therapy is often more effective than people expect. 5-ASAs have very little role in Crohn's disease — despite decades of habit, the evidence is weak.

Corticosteroids (prednisone, IV methylprednisolone, budesonide): Powerful at calming an active flare, useless for maintenance, and harmful when used long-term. Budesonide formulations (Entocort for ileal/right-colon Crohn's; Uceris for UC) are "kinder" steroids with fewer systemic side effects but are still short-term tools. If you can't come off steroids within 3 months, your maintenance therapy needs to change.

Immunomodulators (azathioprine, 6-mercaptopurine, methotrexate): Older pills, slow to work (12–16 weeks), used either as maintenance on their own (less common now) or, more importantly, as "combination therapy" partners alongside anti-TNF biologics to reduce the formation of anti-drug antibodies. Require lab monitoring (CBC, liver enzymes) and a one-time TPMT/NUDT15 genetic test before starting thiopurines. Carry a small but real long-term risk of lymphoma and skin cancer.

Drugs: infliximab (Remicade and biosimilars — IV infusion), adalimumab (Humira and biosimilars — injection at home), certolizumab pegol (Cimzia — injection, Crohn's only in US), golimumab (Simponi — injection, UC only).

How they work: Block TNF-alpha, a key inflammatory signal.

Why they still matter: Two-plus decades of data, fast onset, work for both UC and Crohn's, effective for fistulizing perianal Crohn's (infliximab is first-line), and now far more affordable thanks to biosimilars.

Watch-outs: Infusion reactions (infliximab), injection-site reactions, increased infection risk (must screen for TB and hepatitis B), and the immune system can develop antibodies against the drug ("immunogenicity"), causing it to stop working — this is monitored with therapeutic drug levels.

Key concept — therapeutic drug monitoring (TDM): Blood tests measure the level of drug and whether you've made antibodies against it. If levels are low and you have antibodies, the drug is failing for that reason; if levels are low and no antibodies, you might just need a higher dose; if levels are good but you're flaring, you may need a different mechanism class.

Drug: vedolizumab (Entyvio — IV infusion, with a subcutaneous injection option for maintenance).

How it works: Blocks α4β7 integrin, preventing inflammatory immune cells from trafficking into the gut. Because the action is gut-selective, it has very little effect on the rest of the immune system.

Why it's distinctive: Excellent safety profile — one of the safest biologics in IBD, often preferred for older adults, patients with cancer history, or anyone with infection concerns. Works for both UC and Crohn's.

Watch-outs: Slower to work than anti-TNFs — expect 10–14 weeks for full effect, which is why it's often paired with a course of steroids during induction. Less effective for severe extraintestinal symptoms (joints, skin) because of its gut-selective mechanism.

Drugs:

• Ustekinumab (Stelara — IV induction, then subcutaneous maintenance every 8 weeks): Blocks both IL-12 and IL-23. Approved for both UC and CD. Strong real-world track record. Biosimilars are arriving.
• Risankizumab (Skyrizi — IV induction, subcutaneous maintenance): Selective IL-23 (p19) inhibitor. Approved for Crohn's disease and ulcerative colitis. Very strong endoscopic healing data.
• Guselkumab (Tremfya — IV or fully-subcutaneous induction, then subcutaneous maintenance): Selective IL-23 inhibitor. FDA approved for both ulcerative colitis (September 2024) and Crohn's disease (March 2025).
• Mirikizumab (Omvoh — IV induction, subcutaneous maintenance): Selective IL-23 inhibitor. Approved for both ulcerative colitis (2023, the first selective IL-23 in UC) and Crohn's disease (FDA January 2025, VIVID trials).

Why this class is exploding: Strong efficacy, excellent safety profile (better than anti-TNFs and JAK inhibitors on most measures), low immunogenicity, and convenient maintenance dosing. For many newly diagnosed moderate-to-severe patients, an IL-23 inhibitor is now first-line.

Distinction between IL-12/23 and selective IL-23: Ustekinumab blocks both pathways; the newer drugs block only IL-23 (the p19 subunit). The theory is that preserving IL-12 keeps part of your normal host defense intact, while still blocking the inflammatory IL-23/IL-17 axis. In head-to-head data (SEQUENCE trial: risankizumab vs ustekinumab in Crohn's), selective IL-23 inhibition was superior on endoscopic outcomes.

Drugs: tofacitinib (Xeljanz — pan-JAK, UC only), upadacitinib (Rinvoq — selective JAK1, UC and CD), filgotinib (Jyseleca — selective JAK1, UC; EU-approved only).

How they work: Oral pills that block JAK enzymes inside immune cells, dampening many inflammatory pathways at once.

Why they matter: Very fast onset (some patients improve within a week), oral, and effective even when biologics have failed. Upadacitinib is the only oral therapy currently approved for moderate-to-severe Crohn's disease and provides some of the highest endoscopic remission rates seen in IBD trials.

Watch-outs (boxed warnings): Based on a study in rheumatoid arthritis patients (ORAL Surveillance), JAK inhibitors carry warnings about increased risk of major cardiovascular events, blood clots (VTE), serious infections (including herpes zoster — vaccination with Shingrix is recommended), and certain cancers in people over 50 with cardiovascular risk factors. The IBD population is generally younger and healthier, but these risks should be discussed.

Practical tips: Get the shingles vaccine before starting. Avoid in active smokers over 50 with other cardiovascular risk. Strong option for younger patients with severe disease who want a fast-acting pill and have failed biologics.

Drugs: ozanimod (Zeposia — UC), etrasimod (Velsipity — UC, approved 2023).

How they work: Oral pills that "trap" inflammatory lymphocytes in lymph nodes so they can't traffic to the gut. Different mechanism from JAK inhibitors with a generally cleaner safety profile.

Why they matter: Oral, once-daily, with a more favorable safety signature than JAK inhibitors. Both are approved for UC (no CD approval yet).

Watch-outs: First-dose heart rate slowing (titration schedule required, baseline ECG needed in some patients), small risk of macular edema (baseline eye exam recommended, especially with diabetes), small lung-function effect (baseline PFTs in select patients), and need to be cautious in people with certain cardiac conditions.

For ulcerative colitis: Total proctocolectomy (removing the entire colon and rectum) with ileal pouch-anal anastomosis (IPAA, or "J-pouch") is the standard. After healing, the pouch acts as a small reservoir and most patients have 4–8 bowel movements a day without bags. UC surgery is, in a real sense, curative — without a colon, UC cannot come back, although a complication called "pouchitis" affects roughly 30–50% of pouch patients at some point and is generally treatable. An alternative is end ileostomy with permanent ostomy bag — sometimes preferred by older patients or those with concerns about pouch function.

For Crohn's disease: Surgery is bowel-sparing — the goal is to remove or repair only the diseased segment. Common procedures include ileocecal resection (for ileal/ileocolonic disease), strictureplasty (widening a narrowed segment without removing bowel), perianal surgery (seton placement for fistulas, drainage of abscesses), and segmental colectomy. Crohn's surgery is not curative — the disease can recur in other locations — but it often gives years of better quality of life and is sometimes the most effective treatment.

Timing matters. Operating on someone who is malnourished, on high-dose steroids, and septic has much higher complication rates than operating electively on someone who is optimized. If surgery looks likely, getting in front of it — nutrition optimization, steroid wean, smoking cessation, second opinion from a high-volume IBD surgeon — dramatically improves outcomes.

Diet in IBD is a minefield of unproven advice. Here is what the evidence actually supports:

• Exclusive enteral nutrition (EEN): A formula-only diet for 6–8 weeks. As effective as steroids for inducing remission in pediatric Crohn's, with no side effects. Standard first-line in children with active Crohn's. Some adults can tolerate it as an alternative to steroids.
• Crohn's Disease Exclusion Diet (CDED): A structured diet (often combined with partial enteral nutrition) shown in trials to induce and maintain remission in mild-to-moderate Crohn's, especially in children and young adults.
• Mediterranean diet: Growing evidence as a sustainable, anti-inflammatory eating pattern for IBD maintenance. Generally easier to live with than highly restrictive diets.
• Specific Carbohydrate Diet (SCD) and low-FODMAP diet: Some patients improve symptomatically, but evidence for disease modification is limited. Low-FODMAP can help with overlapping IBS symptoms.

What does not have good evidence: Most online "IBD diets," gluten-free for non-celiac IBD, raw juice cleanses, extreme elimination diets without supervision. Many people lose weight and develop deficiencies trying these.

Always work with a registered dietitian who knows IBD — especially during flares, after surgery, or if considering EEN/CDED.

The STRIDE-II international consensus defines the modern targets for IBD treatment:

• Short-term: Clinical response (symptom improvement) and normalization of CRP/calprotectin.
• Intermediate: Clinical remission off steroids.
• Long-term: Endoscopic healing (Mayo endoscopic subscore 0–1 for UC; absence of ulcers for Crohn's), restored quality of life, no disability.
• Emerging: Histologic healing and transmural healing (no inflammation on biopsy or imaging) — associated with the deepest, most durable remission.

If your current therapy gets you to "feeling better" but your calprotectin is still 800 or your scope shows ulcers, that is no longer considered adequate care. The treatment should be adjusted — optimized doses, combined therapy, or switched.

Biologic medications for IBD can cost $25,000–$80,000 per year at list price. Most patients pay far less — but navigating the financial system takes knowledge. Here is how it works.

Manufacturer copay assistance cards (commercially insured patients): Almost every brand-name biologic has a manufacturer-sponsored copay assistance program. If you have commercial (employer or individual) insurance, these programs can reduce your out-of-pocket cost to $0–$25 per month, regardless of your plan’s copay or deductible. Examples:

• AbbVie myAbbVie Assist → Humira (adalimumab), Rinvoq (upadacitinib), Skyrizi (risankizumab)
• Janssen CarePath → Stelara (ustekinumab), Tremfya (guselkumab)
• Takeda Together with Entyvio → Entyvio (vedolizumab)
• Eli Lilly Lilly Cares → Omvoh (mirikizumab)
• Pfizer RxPathways → Xeljanz (tofacitinib)
• Bristol-Myers Squibb Access Support → Zeposia (ozanimod)
• Pfizer EtraSupport → Velsipity (etrasimod)

Ask your specialty pharmacy to enroll you on your first fill. These programmes are almost universally available and dramatically change the affordability picture.

Medicare and government insurance: Manufacturer copay cards cannot be used with Medicare or Medicaid. Instead:

• Patient assistance programmes (PAPs) — free drug for patients meeting income criteria with no or government insurance.
• HealthWell Foundation, PAN Foundation, Patient Advocate Foundation Co-Pay Relief — grants for Medicare patients.
• Crohn’s & Colitis Foundation IBD Help Center — can identify the right programme for your situation.

Biosimilars — the game-changer for affordability: Multiple FDA-approved biosimilars for infliximab (Remicade) and adalimumab (Humira) are now available at substantially lower cost with the same efficacy and safety. Your insurance plan may require or prefer one. Ask: "Is there a biosimilar that would cost less and work the same?"

Insurance denials: Biologics almost always require prior authorisation. First denials are common and should nearly always be appealed — most initial denials are overturned on peer-to-peer review. Do not accept a denial without appeal.

Many patients starting biologics are anxious about the process. Here is a practical guide to both routes.

Subcutaneous self-injection (adalimumab, ustekinumab SC, vedolizumab SC, risankizumab SC, guselkumab SC):

• Done at home. Auto-injectors or prefilled syringes are delivered refrigerated by specialty pharmacy.
• Remove from fridge 30 minutes before injecting (reduces stinging). Rotate sites (abdomen, thigh, upper arm — never into bruised or scarred skin).
• Clean with an alcohol wipe, press the auto-injector against skin, activate, hold 10 seconds. Done — takes about 30 seconds.
• First injection is usually done in your doctor’s office so a nurse can walk you through it.
• Most common side effect: mild injection-site redness or bruising, usually resolving within an hour.

IV infusion (infliximab, vedolizumab IV, ustekinumab IV induction, risankizumab/guselkumab/mirikizumab IV induction):

• Done at an infusion centre (hospital-based or independent). Budget 2–4 hours total including pre-checks and post-observation.
• What to bring: book, laptop, headphones, snacks. Chairs are generally comfortable recliners. An IV is started in the arm; the nurse monitors vitals before, during, and after.
• Infusion reactions: flushing, headache, or itching can occur. True severe reactions (anaphylaxis) are rare but monitored for. Pre-medication (antihistamine, acetaminophen) is often given for patients with prior reactions.
• Most people feel mildly fatigued on the day of infusion, normal by next day. Some feel notably better in the days after.
• Don’t let doses slip — gaps of even a few weeks can trigger anti-drug antibodies and reduce effectiveness.

Oral pills (JAK inhibitors, S1P modulators): Taken daily by mouth. S1P modulators (ozanimod, etrasimod) require a 7-day titration starter pack to allow heart rate to adjust. Set a phone reminder — consistency matters with oral biologics too.

Therapeutic drug monitoring (TDM) is one of the most powerful tools in modern IBD care — and one of the most underused in some centres. It measures the actual blood level of your biologic medication (and whether antibodies have formed against it) to guide dose optimisation and switching decisions.

Why TDM exists: Biologics are complex proteins. Different patients clear them at very different rates, meaning the same dose can produce very different blood levels. If your level is too low, you don’t get the full anti-inflammatory effect — you may flare even though you are technically "on" the drug. If you develop anti-drug antibodies (ADAs), they neutralise the drug, also causing loss of response.

What a TDM report tells you: For infliximab and adalimumab, TDM measures the drug trough level (amount of drug just before your next dose) and anti-drug antibodies (ADAs). Target trough levels vary by drug and clinical situation, but for infliximab most centres aim for >5–10 µg/mL in active disease; for adalimumab, >7–12 µg/mL.

How TDM guides decisions:

• Low level + high ADA: Immunogenicity — the drug is being neutralised. Dose escalation alone won’t help. Consider switching to a different mechanism class.
• Low level + no ADA: Pharmacokinetic failure — you just need more drug. Dose escalation (higher dose or shorter interval) is usually the answer.
• Adequate level + active disease: Mechanistic failure — the drug is reaching you but the disease isn’t responding to this mechanism. Switch drug class.
• Adequate level + remission: Keep going.

Proactive vs reactive TDM: Forward-thinking IBD centres do proactive TDM — checking levels routinely at planned intervals, even when you feel fine — not just when you flare. Proactive TDM maintains remission longer and reduces loss of response (the PRECISION trial and others support this). Ask your team: "Have you checked my drug levels? What is my target? Are we doing proactive TDM?" If not, consider a second opinion at an IBD centre that does.

You might be surprised to learn that many IBD specialists combine a biologic with an older immunomodulator drug — not because either alone isn’t working, but because the combination performs meaningfully better for a specific reason.

The landmark evidence (SONIC trial): The SONIC trial (2010) showed that combining infliximab + azathioprine produced higher remission and mucosal healing rates than either drug alone in Crohn’s disease. Similar results emerged for UC. The reason is immunogenicity: your immune system can make antibodies against a biologic (anti-drug antibodies), neutralising it and causing loss of response. Immunomodulators (azathioprine/6-MP, methotrexate) suppress the immune cells that produce these antibodies — protecting the biologic from being neutralised.

Practical implications:

• For infliximab and adalimumab, combination with an immunomodulator (usually azathioprine or methotrexate) is well-established and widely recommended, especially in the first 2 years of therapy when immunogenicity risk is highest.
• For newer biologics (vedolizumab, ustekinumab, IL-23 inhibitors), immunogenicity is intrinsically lower. The benefit of combination therapy is less clear and less routinely practised, though some centres still use it.
• For JAK inhibitors and S1P modulators, combination with immunomodulators is generally not used — small molecules are not proteins, so the immunogenicity mechanism doesn’t apply.

Tradeoffs:

• Combination anti-TNF + thiopurine carries a modestly higher risk of serious infections compared to monotherapy.
• Long-term thiopurine use (5+ years) in young males carries a small but real risk of hepatosplenic T-cell lymphoma. This risk decreases significantly with de-escalation of the immunomodulator once the biologic is established and drug levels are stable.
• For many patients, combination therapy is temporary: after 1–2 years of stable remission with adequate drug levels, the immunomodulator is stopped while the biologic continues.

Questions worth asking: "Should I be on combination therapy? How long? When will you check drug levels, and when might we stop the immunomodulator?" The answer should be individualised based on your drug choice, age, gender, risk factors, and drug level trajectory.

• Which class of therapy do you recommend, and why that one specifically?
• What are the realistic chances this drug will work for me, and how long until we'll know?
• What targets are we aiming for — clinical remission, endoscopic healing, normal calprotectin?
• How will we monitor whether the drug is working — calprotectin schedule, drug levels, follow-up scope?
• Should I be on combination therapy (biologic + immunomodulator) or monotherapy?
• Is there a biosimilar version that would be more affordable?
• Do we need to vaccinate me before starting?
• If this drug doesn't work, what's the next step?
• Should I meet a colorectal surgeon now, before I might need them?
• Should I see a dietitian who specializes in IBD?

Track these "early warning" signs and contact your IBD team if any appear:

• Increase in stool frequency, especially with urgency or nighttime episodes
• Visible blood in stool (UC) or worsening abdominal pain (CD)
• New fatigue out of proportion to your usual baseline
• Unintentional weight loss
• New joint pain, eye redness, or skin rash
• Mouth ulcers (especially in Crohn's)
• Fever without an obvious infectious cause
• Rising calprotectin on routine monitoring — often the first signal before symptoms

Many IBD programs use patient portals or rapid-access flare clinics. Use them early. A small flare caught at week 1 is far easier to control than a severe flare presenting to the ER at week 6.

Long-standing colitis (UC or Crohn's colitis) raises the risk of colorectal cancer. The current consensus:

• First surveillance colonoscopy at 8–10 years from diagnosis (earlier if you have primary sclerosing cholangitis — start immediately at PSC diagnosis).
• Frequency thereafter: 1–5 years depending on risk factors (family history, PSC, disease extent, presence of dysplasia, ongoing inflammation).
• Technique: High-definition white light + chromoendoscopy (dye spray) is the modern standard for finding subtle dysplasia.

Patients with PSC have a much higher risk and need annual colonoscopy from PSC diagnosis. Patients with small bowel Crohn's have a higher (but still small) risk of small bowel adenocarcinoma — ask whether MRI enterography includes screening intent.

The most important message: disease control matters more than medication concerns. An active flare during pregnancy is much more dangerous to mother and baby than virtually any IBD medication.

• Anti-TNFs, anti-integrins, anti-IL-23/IL-12-23: All considered low risk in pregnancy and largely continued throughout. Some adjustments to dosing timing in third trimester for anti-TNFs to minimize transfer to the baby.
• Thiopurines (azathioprine, 6-MP): Generally continued in pregnancy.
• Methotrexate: Stop at least 3–6 months before conception (men and women).
• JAK inhibitors: Avoid in pregnancy — switch to a safer alternative before conception.
• S1P modulators: Avoid in pregnancy.
• 5-ASAs and budesonide: Generally safe.
• Live vaccines for the baby (e.g., rotavirus) may need to be delayed if mom was on certain biologics in late pregnancy.

See a high-risk obstetrician familiar with IBD if possible. Preconception counseling — ideally 6–12 months before trying to conceive — is the highest-value intervention.

Anxiety and depression are 2–3 times more common in IBD than in the general population. Fatigue is one of the most disabling symptoms, even in remission. Bathroom urgency, body image issues (especially with ostomy), and the unpredictability of flares can erode mental health.

Effective approaches include:

• Cognitive behavioral therapy, especially gut-directed CBT and hypnotherapy — both have real evidence in IBD.
• Medication when appropriate — SSRIs, low-dose TCAs (which can also help neuromodulation for visceral pain).
• Sleep optimization — sleep is profoundly underrated as a disease modifier.
• Exercise — safe and beneficial in nearly all IBD patients, even during mild flares.
• Peer support — the Crohn's & Colitis Foundation, online communities, in-person groups.

Most IBD therapies suppress at least part of the immune system. A proactive vaccination plan reduces preventable infections:

• Annual influenza vaccine (not live)
• Pneumococcal vaccines (PCV20 or PCV15 + PPSV23 per current schedule)
• Hepatitis B (check titers; vaccinate if not immune)
• HPV per standard schedule
• Shingrix (recombinant zoster) — especially important before JAK inhibitor therapy, recommended starting at age 19 in immunosuppressed patients (current ACIP guidance)
• COVID-19 vaccines per current recommendations — IBD patients generally mount a good response
• MMR and varicella — before starting biologics if non-immune (these are live vaccines and cannot be given on biologics)
• Travel vaccines — plan well in advance; live vaccines (yellow fever) usually cannot be given on biologics

For partners, parents, and other caregivers:

• Understand the relapsing-remitting nature. Your loved one will have weeks or years of feeling well punctuated by flares. Both are normal. Don't interpret a good stretch as "cured" or a flare as failure.
• Take medication adherence seriously together. Missed biologic doses are one of the top causes of relapse. Reminder systems, calendar tracking, and shared awareness help.
• Learn the red flags. Severe pain, high fever, vomiting, distension, large-volume bleeding, signs of obstruction — these warrant urgent contact with the team or an ER visit. Don't wait for "tomorrow."
• Help with the system. Biologics often require insurance pre-authorizations, specialty pharmacy coordination, and infusion scheduling. Sharing this load matters.
• Support nutrition. Meal planning during flares, advocating with dietitians, learning what foods help versus trigger symptoms.
• Validate the invisible symptoms. Fatigue, urgency anxiety, joint pain — these often don't show. Believing them when they're described is care in itself.
• Surgery and stoma support. If surgery is needed, learn about it together. Meet a stoma nurse beforehand. Ostomies are not the end of normal life — many people feel dramatically better after surgery they once feared.
• Watch your own well-being. Chronic illness affects the whole household. Caregiver burnout is real. Seek your own support — partners' groups, individual therapy, time away.

Exercise is one of the most evidence-supported and underused adjunct treatments for IBD. Patients often avoid it out of fear of triggering symptoms — but the evidence consistently shows the opposite: regular physical activity is safe, improves multiple outcomes, and may even have modest anti-inflammatory effects.

What the evidence shows:

• Fatigue: IBD-related fatigue (a top complaint even in remission) is significantly improved by regular aerobic exercise. Multiple trials show reductions in fatigue scores comparable to medication adjustments.
• Mental health: Exercise reduces anxiety and depression in IBD — conditions that are 2–3× more prevalent than in the general population.
• Bone health: Weight-bearing exercise counteracts the bone density loss caused by corticosteroids and chronic inflammation — a real and underappreciated IBD complication.
• Inflammation (modest but real): Moderate aerobic exercise reduces CRP and calprotectin in some IBD studies. It does not replace medication, but it supports the overall remission state.
• Long-term outcomes: Several cohort studies suggest physically active IBD patients have fewer hospitalisations and better long-term disease course than sedentary patients.

What types of exercise work best:

• During remission: Any exercise you enjoy — walking, cycling, swimming, yoga, resistance training, running. Standard recommendations (150 min/week moderate aerobic + 2 strength sessions) apply to IBD patients in remission. Build up gradually.
• During a mild flare: Light activity (walking, gentle yoga, stretching) is generally safe. Avoid high-intensity exercise during moderate-to-severe flares.
• After surgery: Light walking is typically encouraged within days; return to full activity over 4–8 weeks per your surgical team.
• Swimming and yoga: Particularly popular among IBD patients — both avoid urgency concerns that can accompany distance running, and yoga’s stress-reduction benefits add mental health value.

Practical tips: Plan workouts around bathroom access, especially when beginning a new routine. Stay hydrated — IBD patients are more prone to dehydration and electrolyte imbalances. If fatigue is your main complaint, start with 15–20 minutes of walking 3× per week — even small amounts improve fatigue meaningfully. Ask your team for a physiotherapy referral if you have surgery, osteoporosis, joint complications, or significant deconditioning.

IBD affects sexual health, body image, and relationships in ways that are real but rarely discussed in the clinic.

Sexual function and desire:

• During flares, sexual desire and activity are commonly reduced — fatigue, pain, and urgency are obvious barriers.
• Even in remission, studies show lower rates of sexual satisfaction in IBD patients, particularly in women with perianal disease, post-surgical patients, and those with chronic fatigue or depression.
• In Crohn’s disease with perianal involvement, pain, fistulas, and the psychological impact of anal disease can significantly affect sexual function. Effective management of perianal disease matters not just physically but for quality of life.
• Some medications affect sexual function: steroids can reduce libido; sulfasalazine (for mild UC) causes reversible reduction in male sperm count and motility — switching to mesalamine is usually recommended if you are trying to conceive.

Fertility:

• Ulcerative colitis: Disease itself does not reduce fertility. However, IPAA surgery (colectomy with J-pouch) may reduce female fertility by up to 50% due to adhesions near the fallopian tubes. If fertility is a priority and surgery is being considered, discuss fertility-sparing approaches — including preoperative egg freezing — with your surgical team.
• Crohn’s disease: Active disease significantly reduces fertility in both men and women through inflammation, nutritional deficiencies, and systemic effects. Disease control is the most important fertility intervention.
• Methotrexate: Must be stopped at least 3–6 months before conception (men and women). It is teratogenic.
• Biologics in pregnancy: Most are continued through pregnancy — disease activity is far more dangerous to mother and baby than the medications. Preconception counselling 6–12 months before trying to conceive is the highest-value intervention.

Body image and relationships:

• Scars, weight changes from steroids, ostomy bags, and the unpredictability of urgency can profoundly affect body confidence. These feelings are common and valid.
• Open communication with partners reduces burden. Most partners want to understand and help; most feel shut out when the person with IBD suffers in silence.
• Individual or couples counselling with a psychologist familiar with chronic illness can be transformative. Ask your IBD team for a referral.
• The ostomy community (UOAA, online forums) offers peer support from people who have navigated the same challenges — most report quality of life significantly better than expected.

Osteoporosis and reduced bone density are among the most underappreciated long-term complications of IBD. A meaningful proportion of patients are affected — yet many are never screened or counselled about this risk.

Why IBD patients are at higher risk:

• Corticosteroids (the biggest culprit): Prednisone and methylprednisolone rapidly reduce bone density — even relatively short courses (3 months) have measurable effects. The mechanism involves suppressing bone formation and increasing bone resorption. Years of cumulative steroid use can result in significant osteoporosis and fracture risk.
• Chronic inflammation: Pro-inflammatory cytokines (TNF-alpha, IL-6) directly activate osteoclasts (bone-resorbing cells) independently of steroids. Active IBD is itself a bone risk factor.
• Malabsorption: Particularly in Crohn’s disease with small bowel involvement, calcium and vitamin D may be poorly absorbed. Vitamin D deficiency is very common in IBD patients.
• Reduced physical activity during flares and low body weight compound the risk.

Screening: A DEXA scan (bone density X-ray, minimal radiation, 10–15 minutes) is recommended for IBD patients who have used steroids for ≥3 months or who have other risk factors (low BMI, older age, family history, frequent flares). Vitamin D and calcium levels should be checked at least annually.

What you can do:

• Vitamin D supplementation: Target serum 25-OH vitamin D ≥40 ng/mL. Most IBD patients need 2,000–5,000 IU/day — the standard 1,000 IU supplement is often not enough. Ask your team to measure and target your level, not just give a generic dose.
• Calcium: Aim for 1,000–1,200 mg/day from diet + supplement combined. Calcium citrate absorbs without food (often better in IBD patients who have achlorhydria or malabsorption).
• Weight-bearing exercise: Walking, jogging, resistance training — even 30 minutes 3×/week has measurable bone benefit.
• Minimise steroid exposure: One of the strongest reasons to get onto effective maintenance therapy — steroids are for emergencies, not maintenance.
• Bisphosphonates (alendronate, risedronate): If DEXA shows osteoporosis or steroid use is ongoing and prolonged, bisphosphonate therapy is often recommended. Discuss with your team.

• What's my personal flare action plan if symptoms return?
• How often should I do calprotectin testing?
• When is my next colonoscopy or ultrasound due?
• Am I up to date on all recommended vaccines?
• What screening do I need for bone health, skin cancer, and cervical cancer on my current therapy?
• Is there anything I can do to reduce my long-term cancer risk?
• Should I see a mental health provider familiar with chronic illness?
• What's the plan if I want to start a family?

When a biologic stops working, the question is why. Therapeutic drug monitoring can distinguish:

• Low drug level + anti-drug antibodies: Immunogenicity — switch to a different molecule, often a different class.
• Low drug level + no antibodies: Underdosing — intensify dose (more frequent or higher).
• Adequate drug level + active disease: Mechanistic failure — switch to a different mechanism class entirely.

Switching strategies depend on prior failures: after anti-TNF failure, options include vedolizumab, an IL-23 inhibitor (often preferred for primary non-response), a JAK inhibitor (rapid onset for severe disease), or, for UC, an S1P modulator. The order is increasingly individualized.

For patients with severe disease unresponsive to single-agent therapy, combining two advanced therapies (a "dual-targeted" approach) is emerging as a real option. The most common combinations being studied or used in practice include:

• Anti-TNF + vedolizumab (covers gut + systemic)
• Anti-IL-23 + JAK inhibitor or S1P modulator
• Anti-TNF + JAK inhibitor (in selected cases)

The VEGA trial in UC showed that guselkumab + golimumab produced higher remission rates than either alone. Real-world series support dual therapy in carefully selected refractory patients. Dual therapy carries higher infection risk, requires careful monitoring, and is best done at specialized centers.

Perianal Crohn's (fistulas, abscesses, complex fissures) is one of the most challenging IBD problems. It almost always requires a combined surgical + medical approach:

• MRI pelvis to map the fistula anatomy precisely.
• Examination under anesthesia (EUA) with seton placement by a colorectal surgeon to drain abscesses and control infection.
• Biologic therapy: Infliximab is the most-evidenced anti-TNF for fistula closure. Adalimumab is also effective. Newer data support upadacitinib and selective IL-23 inhibitors as well.
• Specialized options: Mesenchymal stem cell therapy (darvadstrocel/Alofisel) is approved in Europe for complex perianal fistulas in Crohn's — not currently available in the US. Ligation of intersphincteric fistula tract (LIFT), endoscopic ablation, and other advanced surgical techniques are emerging.
• Diversion or proctectomy may be needed for severe, treatment-resistant perianal disease.

Severe UC requiring hospitalization is a medical emergency. The standard pathway:

• Admission, IV steroids (methylprednisolone), VTE prophylaxis (blood clot risk is high in flares).
• Day 3 reassessment using the Travis criteria — if not improving, escalate quickly.
• Rescue therapy: Infliximab (often given at accelerated dosing) is the most common; cyclosporine is an alternative; tofacitinib has emerged as a third option, especially as a bridge in patients on biologic therapy already.
• Surgery — colectomy — remains essential and life-saving when medical rescue fails. Delaying surgery in severe UC dramatically increases complications.

An ASUC admission should be managed at a center with a 24/7 IBD-experienced GI and colorectal surgery service.

For refractory disease, clinical trials are often the most reasonable next step — access to mechanisms that aren't yet approved (anti-TL1A drugs such as tulisokibart [formerly PRA023] and duvakitug, obefazimod, and other novel agents), high-quality care, and study-funded monitoring.

• ClinicalTrials.gov — search by condition (Crohn's or UC) and your location.
• Crohn's & Colitis Foundation Clinical Trials Finder — curated, patient-friendly.
• University-affiliated IBD centers — University of Utah Health IBD Center conducts trials and can refer to other institutions if appropriate.
• International registries — for patients with unusual disease or who travel, EU Clinical Trials Information System (CTIS) and others list global studies.

The term "IBD centre" gets used loosely. Here is what genuine specialisation in IBD means, and why it matters for complex disease.

Dedicated IBD-focused gastroenterologists: At high-volume IBD centres, gastroenterologists spend the majority — sometimes all — of their clinical time on IBD specifically. The most recent data on drug optimisation, emerging clinical trial results, and nuanced clinical judgment around TDM and dual-targeted therapy is concentrated among specialists who see IBD every day.

Multidisciplinary care teams: A true IBD centre has the following available and communicating with each other:

• IBD-focused colorectal surgeons (bowel-sparing surgery, complex perianal surgery, pouch surgery, laparoscopic/robotic techniques)
• IBD-trained GI pathologists (interpretation of subtle mucosal biopsies, early dysplasia detection)
• IBD nurses and coordinators (phone triage, flare protocols, pre-authorisation support)
• Registered dietitians specialising in IBD (EEN, CDED, surgical nutrition, ostomy diet)
• Mental health professionals with chronic illness and IBD experience
• Certified wound, ostomy and continence (WOC) nurses

Intestinal ultrasound (IUS) programs: Advanced IBD centres have point-of-care IUS at consultations — providing real-time bowel wall assessment without scheduling a separate test, bowel prep, or radiation. Same-visit treatment decisions become possible.

Proactive TDM protocols: At specialised centres, drug levels are checked systematically, not just when patients fail. Drug level targets are individualised, and dose escalation protocols are used to optimise levels before declaring a biologic a failure.

Clinical trial access: Major IBD centres run Phase 2 and Phase 3 trials. This gives refractory patients access to mechanisms not yet approved (anti-TL1A drugs, novel small molecules, dual-targeted combinations) — potentially years before commercial availability.

High-volume surgical expertise: For ASUC requiring colectomy, complex perianal Crohn’s, IPAA construction, or revision pouch surgery, volume matters. Surgeons who perform 50+ IBD surgeries per year have demonstrably better outcomes than those who perform 5 per year.

How to access a specialty centre: You do not need a referral from your current gastroenterologist, though it is courteous to request one. Major academic IBD centres welcome self-referrals for second opinions. For a life-altering surgical decision or after multiple biologic failures, the trip is worth it.

If you have exhausted one or more biologic classes and are researching what comes next, the anti-TL1A pathway is the most closely watched emerging target in IBD therapeutics as of 2025–2026.

What is TL1A? TNF-like cytokine 1A (TL1A) is a member of the TNF superfamily, elevated in both UC and CD. It drives intestinal inflammation through its receptor DR3 on T cells and innate lymphoid cells. Importantly, TL1A also promotes intestinal fibrosis (scar tissue formation) — making it a particularly interesting target: anti-TL1A therapy may address both active inflammation and the stricture-forming tendency that leads to bowel obstructions in Crohn’s disease.

Lead agents in Phase 3 trials:

• Tulisokibart (formerly PRA023, Merck) — Phase 2 data in both UC (ARTEMIS-UC) and CD (ARTEMIS-CD) were highly promising, with endoscopic remission rates comparable to the best existing biologics. Phase 3 trials are now enrolling (ATLAS programme). Search "tulisokibart" at ClinicalTrials.gov for enrolment sites.
• Duvakitug (TEV-48574, Teva/Sanofi) — Also in Phase 3 after promising Phase 2 results. Search "duvakitug IBD" or the MOUNTAINEER programme at ClinicalTrials.gov.

Why this class is particularly promising for refractory patients:

• Both agents appear to work in patients who have already failed anti-TNF biologics — a critical unmet need, since most other mechanisms (IL-23, vedolizumab) show reduced efficacy in anti-TNF-experienced patients.
• The potential anti-fibrotic effect may be meaningful for Crohn’s patients who have developed fibrostenotic strictures, which currently have no approved medical therapy.
• A genomic biomarker (TL1A gene variant rs6478108) has emerged that may predict which patients respond best — pointing toward precision medicine approaches in IBD.

How to access anti-TL1A therapy now: These agents are not yet FDA-approved. The only current access route is clinical trial participation. Ask your IBD specialist whether you qualify for Phase 3 enrolment, or search ClinicalTrials.gov with keywords "TL1A inflammatory bowel disease." Major IBD centres are enrolment sites.

• Should I be referred to a high-volume specialty IBD center for a second opinion?
• Have we done therapeutic drug monitoring to confirm why my current drug isn't working?
• What dual-targeted therapy combinations would be reasonable for my situation?
• Are there clinical trials I'd qualify for?
• What does my colorectal surgeon think — would surgery actually give me a better quality of life?
• What's the realistic prognosis if we continue trying to control this medically vs going to surgery?

• United States (FDA) — The broadest IBD advanced therapy formulary globally. All five mechanism classes are approved: anti-TNF (infliximab, adalimumab, certolizumab, golimumab), anti-integrin (vedolizumab), anti-IL-12/23 (ustekinumab), selective IL-23 (risankizumab, guselkumab, mirikizumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod). Multiple infliximab and adalimumab biosimilars available.
• European Union (EMA) — Similar to the US, with some additions: filgotinib (Jyseleca) is approved for UC (not available in the US) and darvadstrocel (Alofisel), an allogeneic stem cell therapy for complex perianal Crohn’s fistulas, is EMA-approved but not FDA-approved. Biosimilar availability was earlier and broader in Europe.
• United Kingdom (NICE/MHRA) — NICE Technology Appraisals govern access; most biologics and small molecules are available but subject to step-therapy requirements. BSG guidelines align closely with ECCO. Vedolizumab and ustekinumab are widely used; JAK inhibitors and selective IL-23 agents are available with NICE guidance.
• Japan (PMDA) — All major biologic classes available. Granulocyte-monocyte adsorption apheresis (GMA/Adacolumn) is widely used for UC in Japan but rarely used elsewhere. Japan contributed significant real-world data to anti-TNF and IL-23 inhibitor evidence.
• Canada (Health Canada) — Similar formulary to the US. Strong biosimilar adoption driven by provincial formulary policies. Active IBD research community with major clinical trial enrollment.
• Australia (TGA) — Major biologics and small molecules available. PBS (Pharmaceutical Benefits Scheme) covers most advanced therapies but may require step-therapy documentation. Active IBD clinical trial sites at major teaching hospitals.

• Filgotinib (Jyseleca) — A JAK1-selective inhibitor approved in Europe for UC. The US FDA application was withdrawn over concerns about testicular toxicity (though the MANTA substudy did not confirm the risk). Available in the EU and some other markets.
• Darvadstrocel (Alofisel) — An allogeneic adipose-derived stem cell injection for complex perianal Crohn’s fistulas. EMA-approved based on the ADMIRE-CD trial. Not available in the US. Requires injection by a specialist during examination under anesthesia.
• Granulocyte-monocyte adsorption apheresis (GMA/Adacolumn) — An extracorporeal blood-filtering therapy approved in Japan and some other Asian countries for UC. Evidence is mixed; not widely adopted in Western countries.

Conversely, etrasimod (Velsipity) and some selective IL-23 inhibitors received FDA approval before EMA approval. Timing of availability can differ by months to years between regions.

• Etrolizumab — An anti-beta7 integrin antibody (Roche/Genentech) that completed multiple Phase 3 trials in UC (HICKORY, LAUREL, GARDENIA). The program was discontinued after the trials failed to consistently meet primary endpoints for clinical remission. Despite initial promise as a next-generation gut-selective biologic, it did not demonstrate a clear advantage over existing therapies. FAILED
• Mongersen (GED-0301) — An oral antisense oligonucleotide targeting SMAD7, initially reported dramatic remission rates in a small Phase 2 trial in Crohn’s disease. The Phase 3 REVOLVE trial was terminated in 2017 after an interim analysis showed no benefit over placebo. A cautionary example of promising early data not replicating. FAILED
• Natalizumab (Tysabri) for IBD — An anti-alpha4 integrin antibody that showed efficacy in Crohn’s disease (ENACT, ENCORE trials) but was linked to progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection caused by JC virus reactivation. While still available for MS under a strict risk-management (TOUCH) program, it has been largely abandoned for IBD in favor of the gut-selective vedolizumab, which does not carry PML risk. DE-ADOPTED
• Cyclosporine for maintenance UC — IV cyclosporine remains an effective rescue therapy for acute severe UC. However, long-term oral cyclosporine maintenance was studied and found to have poor tolerability and high relapse rates. It has been replaced by bridge-to-thiopurine or bridge-to-biologic strategies. DE-ADOPTED
• Mesalamine (5-ASA) for Crohn’s disease — Despite decades of widespread use, high-quality evidence consistently shows that mesalamine has little to no benefit in Crohn’s disease (induction or maintenance). AGA and ECCO guidelines now recommend against its use for CD, though it is still sometimes prescribed out of habit. DE-ADOPTED
• Antibiotics as primary maintenance therapy — Metronidazole and ciprofloxacin were historically used as long-term maintenance treatments for Crohn’s disease. Evidence does not support this practice, and long-term use carries significant side effects (peripheral neuropathy with metronidazole, tendinopathy with ciprofloxacin). Antibiotics now have a narrow role: short courses for perianal abscess/fistula and post-operative prophylaxis. DE-ADOPTED
• Fontolizumab — An anti-interferon-gamma antibody tested in Crohn’s disease in the mid-2000s. Phase 2 results were modest and the program was discontinued. FAILED

• University of Utah Health IBD Center (Salt Lake City) — multidisciplinary IBD care including gastroenterology, colorectal surgery, IBD-specialized GI pathology, biologic infusion center, intestinal ultrasound program, dedicated IBD nursing, dietitian, mental health, and active clinical trials enrollment.
• Intermountain Health gastroenterology services — widespread GI care across the Wasatch Front and beyond, with biologic infusion infrastructure.
• Primary Children's Hospital (pediatric IBD) — comprehensive pediatric IBD program with transition-to-adult care.
• Crohn's & Colitis Foundation, Utah chapter — local education events, "Take Steps" walks, Camp Oasis (a free summer camp for children with IBD), peer support, patient education materials, and the "I Can't Wait" bathroom request card (a discreet card you can carry to request restroom access in stores and businesses).
• Utah Ostomy Association — community for patients with ileostomies, colostomies, and J-pouches.

• Crohn's & Colitis Foundation (crohnscolitisfoundation.org) — patient education, advocacy, research funding, clinical trial finder, IBD Help Center.
• American Gastroenterological Association (AGA) patient resources — aga.org.
• UOAA (United Ostomy Associations of America) — ostomy support, advocacy, and educational resources.
• European Crohn's & Colitis Organisation (ECCO) — gold-standard international IBD guidelines, accessible at ecco-ibd.eu.
• Crohn's & Colitis UK, Canada, Australia, and others — high-quality patient information; useful even for US patients.

• Manufacturer copay assistance programs for most brand-name biologics (Stelara, Skyrizi, Tremfya, Entyvio, Rinvoq, Velsipity, Zeposia, etc.) — often dramatically reduce out-of-pocket costs for commercially insured patients.
• Independent patient assistance foundations (HealthWell Foundation, Patient Access Network, Patient Advocate Foundation) — for Medicare patients who can't use manufacturer copay programs.
• Biosimilars — infliximab and adalimumab biosimilars are widely available, often at lower cost. Ask your team if switching is appropriate.
• Insurance appeals — if a biologic is denied, your IBD team can write peer-to-peer appeals. Most initial denials get overturned.
• Crohn's & Colitis Foundation IBD Help Center — can assist with insurance and access navigation.

Ideal members of a well-rounded IBD care team:

• IBD-focused gastroenterologist (your quarterback)
• Colorectal surgeon experienced in IBD (meet before you need them)
• Registered dietitian familiar with IBD
• Mental health provider (psychologist or psychiatrist) familiar with chronic GI disease
• IBD nurse or care coordinator for day-to-day questions and pre-auth navigation
• Primary care physician for general health and preventive care
• Specialty pharmacy for biologic delivery
• For specific situations: rheumatologist (joint disease), dermatologist (skin manifestations), hepatologist (PSC), ophthalmologist (uveitis), high-risk OB (pregnancy), pain specialist (chronic abdominal pain)

IBD is recognized as a disability under the Americans with Disabilities Act (ADA), which means you may be entitled to reasonable workplace accommodations:

• Unrestricted and immediate restroom access
• Flexible scheduling for medical appointments and infusion days
• Work-from-home arrangements during flares
• Extended break times when needed

For students, Section 504 plans or IEPs can secure accommodations in K–12 settings (restroom passes, extended test time, excused absences). College students should contact their disability services office.

You do not need to disclose your specific diagnosis — only the functional limitations that require accommodation.

• Medication logistics: Carry biologics in insulated cooler bags for temperature-sensitive drugs (adalimumab, vedolizumab SC). Bring a doctor's letter for TSA/customs explaining injectable medications. Always carry medications in hand luggage.
• Plan ahead: Identify infusion centers or pharmacies at your destination. Many biologic manufacturers have travel programs to arrange infusions away from home.
• Vaccinations: Consult a travel medicine clinic well in advance — some live vaccines (yellow fever) cannot be given on immunosuppressants.
• Insurance: Verify coverage outside your state/country. Travel medical insurance is strongly recommended for international travel.
• Flare kit: Carry a supply of steroids (budesonide or prednisone), antidiarrheals, and electrolyte solutions. Have your IBD team's emergency contact information easily accessible.

Despite the impressive expansion of IBD therapy, access remains uneven:

• Insurance step-therapy requirements sometimes force older or less-suitable drugs to be tried first. Push back with your team's help when the science doesn't support it.
• Rural and small-town access to IBD-specialized GI and surgery is limited. Travel for at least an initial second opinion is often worth it.
• Therapeutic drug monitoring is still under-used — if your doctor doesn't routinely check drug levels, ask why.
• Intestinal ultrasound is available at major centers but not yet universal. It is a major value-add when accessible.
• International availability varies: filgotinib and darvadstrocel are EU-only; some biosimilars approved abroad are not yet in the US.
• Mental health integration in IBD care is improving but is far from universal. Advocate for it.

This guide is general educational information for patients and caregivers and is not a substitute for individualized medical advice from a qualified clinician who knows your full history. Drug approvals, dosing, and contraindications evolve rapidly — always verify with your current treating team and prescribing information. Anecdotes, online forums, and "what worked for someone else" are not data. Never stop or change medications without consulting your IBD team, even if you feel better. Emergencies (severe pain, bleeding, fever, obstruction, signs of perforation or abscess) require immediate medical evaluation, not online research.

The prospect of an ostomy or J-pouch surgery is one of the most feared outcomes for IBD patients. The reality — reported consistently by people who have lived with both active IBD and with an ostomy — is often very different from what patients imagine beforehand.

Types of surgical anatomy after IBD surgery:

• End ileostomy: The small intestine is brought out through a stoma (opening) in the abdominal wall. Output drains into a bag (pouch appliance) on the skin. Common after colectomy for UC, or when the rectum is also removed.
• IPAA (J-pouch): The colon and rectum are removed, and a reservoir fashioned from the end of the small intestine is connected directly to the anus. No external bag. After healing (typically 3–6 months and a second surgery to "take down" a temporary ileostomy), the patient has 4–8 bowel movements per day. Most people describe this as dramatically better than active UC.
• Loop ileostomy (temporary): Often created as a protecting stoma during J-pouch construction; reversed once the pouch heals.

What daily life actually looks like:

• Diet: Modified in the weeks after surgery (soft, low-fibre, low-residue). Over time most ostomates expand substantially through trial and observation. Chew thoroughly, stay hydrated, eat small meals regularly.
• Appliance management: Modern ostomy appliances (two-piece wafer + pouch, or one-piece systems) are far more discreet, reliable, and odour-controlled than most patients imagine. A certified WOC nurse trains you in selection, sizing, and pouch changes — which typically take 10–15 minutes every 3–5 days.
• Swimming and sports: Waterproof covers, stoma caps, and modern appliances allow swimming, contact sports, and all forms of exercise. Most ostomates return to every physical activity they enjoyed before.
• Intimacy: Stoma wraps, high-waisted underwear, and ostomy lingerie help with body confidence. Open conversation with partners matters; most partners adapt readily.
• Travel: Carry extra supplies in hand luggage (never checked). A travel letter from your surgeon for airport security. Customs/TSA cannot require you to empty or display the ostomy bag. Most airlines allow extra liquids for stoma care supplies.

The adjustment arc: Studies consistently show that quality-of-life scores for ostomates — after an adjustment period of approximately 6–12 months — are often equal to or higher than quality-of-life scores for people living with active IBD on medical therapy. The fear before surgery rarely matches the reality after it. Peer support from established ostomates (UOAA, Crohn’s & Colitis Foundation ostomy networks, "Ostomy Outdoors") is one of the most powerful resources in the adjustment period.

The relationship between IBD and mental health runs in both directions — and taking it seriously changes outcomes.

How common: Depression affects 15–25% of IBD patients (2–3× the general population rate). Anxiety affects 20–40%, often driven by bathroom urgency anxiety, fear of flares, and anticipatory worry about social situations. Approximately 30–40% of patients in clinical remission report significant impact on daily functioning from fatigue, mental health symptoms, or social limitations.

The bidirectional connection:

• IBD → mental health: Chronic pain, unpredictable symptoms, social limitations, body image changes, and the burden of a lifelong diagnosis drive anxiety and depression directly.
• Mental health → IBD: Psychological stress activates the HPA axis, alters gut permeability, changes microbiome composition, and modulates intestinal immune signalling — potentially triggering or worsening flares. High perceived stress independently predicts future flares in IBD, even controlling for medication adherence.
• Shared biology: The gut and brain communicate via the vagus nerve, gut-derived neurotransmitters (serotonin, GABA), and microbiome metabolites. In IBD this communication is disrupted, contributing to functional GI symptoms that persist even in biological remission.

What actually helps:

• Cognitive behavioural therapy (CBT): The most evidence-based psychological therapy for IBD. Gut-directed CBT improves quality of life, reduces anxiety, and in some studies improves biological markers of inflammation.
• Gut-directed hypnotherapy: Genuine evidence for reducing symptom burden and psychological distress in IBD.
• SSRIs and SNRIs: Appropriate and effective for depression and anxiety in IBD. Low-dose tricyclic antidepressants (TCAs) also reduce visceral hypersensitivity (gut pain sensitivity) — a useful dual benefit for some patients.
• Peer support groups: Consistently improves psychological wellbeing. The Crohn’s & Colitis Foundation facilitates groups nationwide.

How to access support: Ask your IBD team for a referral to a psychologist, social worker, or psychiatrist familiar with chronic physical illness. In Utah, the University of Utah Health Behavioral Health Clinics and Intermountain Health mental health services both have experience with chronic illness patients. An embedded mental health professional within your IBD programme — where one exists — is the gold standard.

• IBD (Inflammatory Bowel Disease) — An umbrella term for chronic conditions in which the digestive tract becomes inflamed. The two main types are Crohn's disease and ulcerative colitis.
• Crohn's disease (CD) — A form of IBD that can affect any part of the digestive tract from mouth to anus. Inflammation often occurs in patches and can extend through the full thickness of the bowel wall.
• Ulcerative colitis (UC) — A form of IBD limited to the colon (large intestine) and rectum. Inflammation is continuous (no skipped areas) and affects only the inner lining of the bowel.
• Anti-TNF — A class of biologic medications (such as infliximab and adalimumab) that block tumor necrosis factor, a protein that drives inflammation. These were the first biologics approved for IBD.
• Vedolizumab (anti-integrin) — A biologic that works specifically in the gut by blocking a protein (integrin) that guides immune cells into intestinal tissue, reducing inflammation without broadly suppressing the immune system.
• Ustekinumab (anti-IL-12/23) — A biologic that blocks two inflammatory signaling molecules, IL-12 and IL-23. It is used for moderate-to-severe Crohn's disease and ulcerative colitis.
• Risankizumab / Guselkumab (anti-IL-23) — Newer biologics that selectively block only IL-23, a key driver of gut inflammation. They are among the most recently approved treatments for IBD.
• JAK inhibitor (tofacitinib, upadacitinib) — Small-molecule pills (not injections) that work inside cells by blocking Janus kinase enzymes, which relay inflammatory signals. They act quickly and are taken by mouth.
• S1P modulator (ozanimod, etrasimod) — Oral medications that trap certain immune cells in lymph nodes, preventing them from traveling to the gut and causing inflammation. Used for ulcerative colitis.
• Biologic — A medication made from living cells (usually given by injection or infusion) that targets a specific part of the immune system to reduce inflammation. Examples include anti-TNF agents and vedolizumab.
• Biosimilar — A biologic medication that is highly similar to an already-approved biologic (the "reference product") with no meaningful differences in safety or effectiveness. Biosimilars are typically less expensive.
• Calprotectin — A protein released by white blood cells in the intestine. Measured with a simple stool test, elevated calprotectin indicates active gut inflammation and is used to monitor IBD without needing a colonoscopy.
• Treat-to-target — A strategy where your IBD team sets specific measurable goals (such as normal calprotectin levels and healed intestinal lining) and adjusts treatment step by step until those targets are met.
• ASUC (Acute Severe Ulcerative Colitis) — A medical emergency in which ulcerative colitis flares so severely that hospitalization is required. Symptoms include frequent bloody stools, rapid heart rate, fever, and anemia.
• Fistula — An abnormal tunnel that forms between two body parts, such as between loops of intestine or between the intestine and the skin. Fistulas are a complication seen mainly in Crohn's disease.
• Stricture — A narrowing of a section of the intestine caused by chronic inflammation and scarring. Strictures can partially or fully block the passage of food and may require dilation or surgery.
• Colectomy — Surgical removal of part or all of the colon. In ulcerative colitis a total colectomy can be curative; in Crohn's disease surgery removes damaged segments but does not cure the underlying condition.
• IPAA (Ileal Pouch-Anal Anastomosis) — A surgical procedure performed after colectomy in which a pouch is created from the end of the small intestine and connected to the anus, allowing bowel movements without a permanent ostomy bag.
• TDM (Therapeutic Drug Monitoring) — Regular blood tests that measure the level of a biologic medication (and antibodies against it) in your bloodstream. TDM helps your doctor confirm the dose is right and detect problems early.